Drug related problems with Antiparkinsonian agents: Consumer internet reports versus published data

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 10, 2007, Pages 1161-1166

  Schröder, Sabrina ^a   Zöllner, York Francis ^b   Schaefer, Marion ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Adverse drug reactions; Antiparkinsonian agents; Consumer reports; Drug related problems; Internet; Parkinson's disease; Pharmacovigilance

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CABERGOLINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; TOLCAPONE;

ADDICTION; AGGRESSION; ALOPECIA; ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; COGNITION; CONSTIPATION; CONSUMER HEALTH INFORMATION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG STORAGE; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSPNEA; ECG ABNORMALITY; EYE DISEASE; FATIGUE; HALLUCINATION; HEART ARRHYTHMIA; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERSEXUALITY; INCREASED APPETITE; INSOMNIA; INTERNET; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL DISEASE; MIGRAINE; MUSCLE DISEASE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PIGMENT DISORDER; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RESTLESSNESS; SELF REPORT; SIDE EFFECT; SKIN ALLERGY; SKIN EDEMA; SLEEP DISORDER; SLEEP WAKING CYCLE; SOMNOLENCE; STOMACH DISEASE; URINARY FREQUENCY; VALVULAR HEART DISEASE; VISUAL DISORDER; VIVID DREAM; WEIGHT GAIN; WOUND HEALING; XEROSTOMIA;

ANTIPARKINSON AGENTS; DATA COLLECTION; HUMANS; INTERNET; RETROSPECTIVE STUDIES;

EID: 35648951718     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1415     Document Type: Article

References (22)

1. Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004; 52: 1349-1354.
2. van Mil JWF. Proceedings of the International Working Conference on Outcomes Measurement in Pharmaceutical Care. Pharmaceutical Care Network Europe (PCNE) Hilleroed, Denmark, 1999; 9: 84.
3. Shimbo T, Goto M, Morimoto T, et al. Association between patient education and health-related quality of life in patient with Parkinson's disease. Qual Life Res 2004; 13: 81-89.
4. Chan DK. The art of treating Parkinson disease in the older patient. Aus Fam Physician 2003; 32: S927-S931.
5. Midlöv P, Bondesson A, Eriksson T, et al. Descriptive study and pharmacotherapeutic intervention in patients with epilepsy or Parkinson's disease at nursing homes in southern Sweden. Eur J Clin Pharmacol 2002; 57: 903-910.
6. Schaefer M, Schulz M. Manuale zur Pharmazeutischen Betreuung, Band 1, Grundlagen der Pharmazeutischen Betreuung. Eschborn: Govi-Verlag, 2000; 24.
7. Strand LM, Morley PC, Cipolle RJ, et al. Drug-related problems: their structure and function. DICP 1990; 24:1093-1097.
8. van Mil JWF, Westerlund T, Hersberger KE, et al. Drug-related problem classification systems. Ann Pharmacother 2004; 38: 859-867.
9. Schaefer M. Discussing basic principles for a coding system of drug-related problems: the case of PI-Doc®. Pharm World Sci 2002; 24: 120-127.
10. Reichmann H, Engfer A, Jost W, et al., Morbus Parkinson Nebenwirkungs- und Interaktionsdatenbank. URN: urn:nbn:de: 0007-21663019 (www.parkinson-datenbank.de) [Accessed on 12 December 2005].
11. ATC-Index. Anatomisch-therapeutisch-chemische-Klassifikation mit Tagesdosen. Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahr 2005. Status: 1 January 2005.
12. Chaudhuri KR, Morley PC, Cipolle RJ. Sleep attacks or unintended sleep episodes occur with dopamine agonists: is it a class effect? Drug Saf 2002; 25: 473-483.
13. Schlesinger I, Ravin PD. Dopamine agonists induce episodes of irresistible daytime sleepiness. Eur Neurol 2003; 49: 30-33.
14. World Health Organisation. Direct reportring by consumers: first international conference. WHO Pharmaceutical Newsletter 2000; 3: 12-13.
15. van Grootheest K, de Jong-van den Berg LTW. Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf 2004; 3: 363-368.
16. van Grootheest K, de Graaf L, de Jong-van den Berg LTW. Consumer adverse drug reaction reporting. A new step in pharmacovigilance? Drug Saf 2003; 26:211-217.
17. Jopp R. Das Internet als Datenquelle zur Identifikation, Erhebung und Analyse arzneimittelbezogener Patientenfragen. Dissertationsschrift. Humboldt-Universtät zu Berlin 2002.
18. Morel P, Vandel B. Adverse drug reaction monitoring and the Internet: evaluation of the use of the Internet by French pharmacovigilance centres and a non-exhaustive survey of websites of interest for collecting information about adverse drug reaction. Thérapie 1999; 54: 525-532.
19. Mitchell AS, Henry DA, Sanson-Fischer R, et al. Patients as a direct source of information on adverse drug reactions. BMJ 1988; 297: 891-893.
20. Solovitz BL, Fisher S, Bryand SG, et al. How well can patients discriminate drug-related side effects from extraneous new symptoms? Psychopharmacol Bull 1987; 23: 189-195.
21. Zrebiec JF, Jacobson AM. What attracts patients with diabetes to an Internet support group? A 21-month longitudinal website study. Diabet Med 2001; 18: 154-158.
22. Buchner J, Chrostek M, Diabetes FAQ. 2000; www.diabeticus.de/faq/> [Accessed on 13 November 2005].